Associated Papers
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_4.xlsx › EGFR_mutations
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
35244186 (PubMed )
Supplement: Supplementary_Data2.xlsx › Feuil1
ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications.
Jin W
Journal of Clinical Medicine, 2020
Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis.
Liu H et al.
Cancer Communications (london, England), 2020
32067422 (PubMed )
Supplement: CAC2-40-43-s001.xlsx › Table_S1
Evolution of oncogenic signatures of mutation hotspots in tyrosine kinases supports the atavistic hypothesis of cancer.
Chen W et al.
Scientific Reports, 2018
29844492 (PubMed )
Supplement: 41598_2018_26653_MOESM2_ESM.xlsx › Dataset_S1
Distribution of somatic mutations of cancer-related genes according to microsatellite instability status in Korean gastric cancer.
Park J et al.
Medicine, 2017
Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.
McMillen E et al.
Experimental Lung Research, 2010
Select a paper to view details